These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 28158470)

  • 41. Pharmacodynamics of Aerosolized Fosfomycin and Amikacin against Resistant Clinical Isolates of Pseudomonas aeruginosa and Klebsiella pneumoniae in a Hollow-Fiber Infection Model: Experimental Basis for Combination Therapy.
    Sime FB; Johnson A; Whalley S; Santoyo-Castelazo A; Montgomery AB; Walters KA; Lipman J; Hope WW; Roberts JA
    Antimicrob Agents Chemother; 2017 Jan; 61(1):. PubMed ID: 27795380
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pharmacokinetics-Pharmacodynamics of a Novel β-Lactamase Inhibitor, CB-618, in Combination with Meropenem in an In Vitro Infection Model.
    VanScoy BD; Trang M; McCauley J; Conde H; Bhavnani SM; Friedrich LV; Alexander DC; Ambrose PG
    Antimicrob Agents Chemother; 2016 Jul; 60(7):3891-6. PubMed ID: 27001820
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Activities of piperacillin, ceftazidime, cefepime and cefpirome against Pseudomonas aeruginosa strains with intrinsic ticarcillin resistance.
    Bert F; Setbon PG; Lambert-Zechovsky N; Branger C
    Chemotherapy; 1996; 42(6):426-31. PubMed ID: 8957576
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Effect of inhibitory (MIC) and subinhibitory concentrations of tobramycin on bacteriostatic and bactericidal activities of beta-lactam antibiotics (author's transl)].
    Masuda G; Yajima T; Nakamura K; Yanagishita T; Yamazaki E
    Jpn J Antibiot; 1979 Nov; 32(11):1189-95. PubMed ID: 117156
    [No Abstract]   [Full Text] [Related]  

  • 45. In vitro pharmacodynamics of various antibiotics in combination against extensively drug-resistant Klebsiella pneumoniae.
    Lim TP; Cai Y; Hong Y; Chan EC; Suranthran S; Teo JQ; Lee WH; Tan TY; Hsu LY; Koh TH; Tan TT; Kwa AL
    Antimicrob Agents Chemother; 2015 May; 59(5):2515-24. PubMed ID: 25691628
    [TBL] [Abstract][Full Text] [Related]  

  • 46. In vitro effect of subinhibitory concentrations of ceftazidime and meropenem on the serum sensitivity of Pseudomonas aeruginosa strains.
    Drenjancević D; Vranes J; Bedenić B; Sakić-Zdravcević K
    Coll Antropol; 2007 Mar; 31(1):221-5. PubMed ID: 17598405
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Fourth-generation cephalosporins: in vitro activity against nosocomial gram-negative bacilli compared with beta-lactam antibiotics and ciprofloxacin.
    Tumah H
    Chemotherapy; 2005 May; 51(2-3):80-5. PubMed ID: 15870501
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pharmacodynamic modeling of carbapenems and fluoroquinolones against bacteria that produce extended-spectrum beta-lactamases.
    Moczygemba LR; Frei CR; Burgess DS
    Clin Ther; 2004 Nov; 26(11):1800-7. PubMed ID: 15639692
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Comparison of antimicrobial activity between ceftolozane-tazobactam and ceftazidime-avibactam against multidrug-resistant isolates of Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa.
    Alatoom A; Elsayed H; Lawlor K; AbdelWareth L; El-Lababidi R; Cardona L; Mooty M; Bonilla MF; Nusair A; Mirza I
    Int J Infect Dis; 2017 Sep; 62():39-43. PubMed ID: 28610832
    [TBL] [Abstract][Full Text] [Related]  

  • 50. In vitro activity of combination therapy with cefepime, piperacillin-tazobactam, or meropenem with ciprofloxacin against multidrug-resistant Pseudomonas aeruginosa strains.
    Erdem I; Kucukercan M; Ceran N
    Chemotherapy; 2003 Dec; 49(6):294-7. PubMed ID: 14671429
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Antimicrobial Effects of β-Lactams on Imipenem-Resistant Ceftazidime-Susceptible Pseudomonas aeruginosa.
    Wi YM; Choi JY; Lee JY; Kang CI; Chung DR; Peck KR; Song JH; Ko KS
    Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28373200
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Simple method to determine beta-lactam resistance phenotypes in Pseudomonas aeruginosa using the disc agar diffusion test.
    Vedel G
    J Antimicrob Chemother; 2005 Oct; 56(4):657-64. PubMed ID: 16144872
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Comparison of different phenotypic methods detecting extended spectrum beta-lactamases in Pseudomonas aeruginosa and Acinetobacter baumannii strains].
    Zarakolu P; Metan G; Hasçelik G; Akova M
    Mikrobiyol Bul; 2005 Jul; 39(3):265-72. PubMed ID: 16358485
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Reevaluation of Enterobacteriaceae MIC/disk diffusion zone diameter regression scattergrams for 9 beta-lactams: adjustments of breakpoints for strains producing extended spectrum beta-lactamases.
    Jones RN; Craig WA; Ambrose PG; Dudley MN; Pottumarthy S
    Diagn Microbiol Infect Dis; 2005 Jul; 52(3):235-46. PubMed ID: 16105568
    [TBL] [Abstract][Full Text] [Related]  

  • 55. In vitro activity of beta-lactam antimicrobial agents in combination with aztreonam tested against metallo-beta-lactamase-producing Pseudomonas aeruginosa and Acinetobacter baumannii.
    Sader HS; Rhomberg PR; Jones RN
    J Chemother; 2005 Dec; 17(6):622-7. PubMed ID: 16433192
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Pharmacokinetic and experimental data on beta-lactam antibiotics in the treatment of patients.
    Craig W
    Eur J Clin Microbiol; 1984 Dec; 3(6):575-8. PubMed ID: 6441711
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Previous ciprofloxacin exposure is associated with resistance to beta-lactam antibiotics in subsequent Pseudomonas aeruginosa bacteremic isolates.
    López-Dupla M; Martínez JA; Vidal F; Almela M; Soriano A; Marco F; López J; Olona M; Mensa J
    Am J Infect Control; 2009 Nov; 37(9):753-8. PubMed ID: 19487049
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effect of beta-lactam antibiotics on the in vitro development of resistance in Pseudomonas aeruginosa.
    Carsenti-Etesse H; Cavallo JD; Roger PM; Ziha-Zarifi I; Plesiat P; Garrabe E; Dellamonica P
    Chirurgia (Bucur); 2002; 97(2):151-9. PubMed ID: 12731225
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pharmacodynamic modeling of intravenous antibiotics against gram-negative bacteria collected in the United States.
    Koomanachai P; Bulik CC; Kuti JL; Nicolau DP
    Clin Ther; 2010 Apr; 32(4):766-79. PubMed ID: 20435246
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Antimicrobial Activities of Ceftazidime-Avibactam and Comparator Agents against Clinical Bacteria Isolated from Patients with Cancer.
    Hachem R; Reitzel R; Rolston K; Chaftari AM; Raad I
    Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28115350
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.